Teva reveals Copaxone sales
Israel's Teva Pharmaceutical Industries says that global in-market sales of Copaxone (glatiramer) in the first quarter of 2008 grew by 35% on the first quarter of 2007 and reached a quarterly record of $542.0 million. Under an agreement with French drug major Sanofi-Aventis, the Israeli company assumed responsibility for the distribution of this MS drug in the USA and Canada from April 1 this year.
In the USA, after achieving sales leadership in the MS market in 2007, Copaxone continues the trend of growth in both sales and sector share with first quarter net turnover of $311.0 million, an increase of 20%.
Copaxone continues to gain market share outside the USA as well, with ex-US revenues increasing 64% to reach $231.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze